Men with higher levels of melatonin may have a lower risk of developing prostate cancer (PCa), according to a study presented at the American Association for Cancer Research-Prostate Cancer Foundation Conference on Advances in Prostate Cancer Research in San Diego.
Sarah C. Markt, MPH, from the Harvard School of Public Health in Boston, and colleagues examined the association between urinary 6-sulfatoxymelatonin concentrations, sleep patterns, and the risk of PCa in 928 Icelandic men from 2002 to 2009, of whom 111 were newly diagnosed with PCa, including 24 with advanced disease. The median concentration of 6-sulfatoxymelatonin was 17.14 ng/mL. Levels of 6-sulfatoxymelatonin were significantly lower in men who reported sleep problems at baseline. After adjusting for potential confounders, men with high levels of 6-sulfatoxymelatonin had a significant 75% decreased risk of PCa.
“Higher urinary 6-sulfatoxymelatonin levels were associated with a decreased risk of prostate cancer, particularly advanced disease,” Markt and colleagues conclude.